Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

Psilocybin, the main psychoactive ingredient in magic mushrooms, could alleviate depression for at least five years after just one dose, according to a new study.

If Island Pharma’s drug keeps delivering, it could fast-track approval. And in a world with millions of dengue cases a year, ...

Creatine, a naturally occurring compound, enhances athletic performance and shows potential health benefits, but caution and ...

The ADDF’s CFO discusses the areas that foundation is raising money for and how its reacting to the current economic ...

NKGen Biotech has activated two new trial sites in Canada and Florida, US, for the Phase I/IIa study of its cryopreserved expanded autologous natural killer (NK) cell therapy, troculeucel, in patients ...

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...

Skin grafts genetically engineered from a patient's own cells can heal persistent wounds in people with an extremely painful ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall ...